drugset / Trial / NCT04466917
A Study of ABP 215 Versus Bevacizumab in Chinese Subjects With Advanced Non-Squamous Non-Small Cell Lung Cancer
RandomizedParallel-groupQuadruple-blindTreatment
Summary
The purpose of this research study is to assess the efficacy and safety of ABP 215 compared to Bevacizumab in Chinese patients with advanced non-small cell lung cancer (NSCLC).
Timeline
- Start
- 2021-05-15
- Primary completion
- 2022-11-13
- Completion
- 2022-11-13
Outcome
Outcome not reported
Stopped (Business): “Sponsor decision to early terminate the study”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | ABP 215 | Unknown | 15 mg/kg | Intravenous |
| Comparator | Bevacizumab | Monoclonal antibody | 15 mg/kg | Intravenous |
| Background | Carboplatin | Small molecule | 5 unknown | Intravenous |
| Background | Paclitaxel | Small molecule | 175 mg/m2 | Intravenous |